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2ABSTRACT
The rising epidemic of Type 2 diabetes (T2DM) worldwide is of significant concern. The
inherently silent nature of the disease in its early stages precludes early detection; hence
cardiovascular disease is often established by the time diabetes is diagnosed. This increased
cardiovascular risk leads to significant morbidity and mortality in these individuals.
Progressive development of complications as a result of previous exposure to metabolic
disturbances appears to leave a long-lasting impression on cells of the vasculature that is not
easily reversed and termed “metabolic memory”.
Smooth muscle cells (SMC) of blood vessel walls, through their inherent ability to
switch between a contractile quiescent phenotype and an active secretory state, maintain
vascular homeostasis in health and development. This plasticity also confers SMC with the
essential capacity to adapt and remodel in pathological states. Emerging clinical and
experimental studies propose that SMC in diabetes may be functionally impaired and thus
contribute to the increased incidence of macrovascular complications. Although this idea has
general support, the underlying molecular mechanisms are currently unknown and hence the
subject of intense research.
The aim of this review is to explore and evaluate current literature relating to the
problem of vascular disease in T2DM and discuss the critical role of SMC in vascular
remodelling. Possibilities for therapeutic strategies specifically at the level of T2DM-SMC,
including recent, novel advances in the areas of microRNAs and epigenetics will be
evaluated. Since restoring glucose control in diabetes patients has limited effect in
ameliorating their cardiovascular risk, discovering alternative strategies that restrict or reverse
disease progression is vital. Current research in this area will be discussed.
31. Introduction
1.1 Prevalence of type 2 diabetes and cardiovascular risk
Gradual decline of vascular function is a consequence of normal aging that manifests as
structural and biochemical changes in blood vessel walls that gradually compromise vascular
health [1]. Insulin resistance leading to type 2 diabetes (T2DM) is a chronic metabolic and
inflammatory condition [2] and a recognised cause of accelerated vascular aging [3].
Although T2DM is initially symptomless and likely present for years, in the long term it is
associated with debilitating cardiovascular complications and premature death. It is perceived
that up to half of patients have evidence of cardiovascular complications by the time diabetes
is diagnosed [4] and that mortality from T2DM-related cardiovascular disease reportedly
confers a risk equivalent to 15 years of aging [5]. In the UK alone, the number of people
diagnosed with T2DM has increased from 1.4 million in 1996 to 2.9 million in 2011
(diabetes.org.uk), with an inevitable impact on healthcare costs reportedly accounting for £9
billion per annum - approximately 10% of the entire NHS budget. These alarming figures are
attributable not only to an aging population but importantly to the rising epidemic of obesity
and physical inactivity.
The complications of T2DM encompass a diverse range of pathologies of the large
and small arteries. In addition, diabetes patients are vulnerable to a distinctive
cardiomyopathy independent of coronary artery disease that underlies progression to heart
failure [6]. Microvascular (principally retinopathy, nephropathy) and neuropathic
complications can, to a significant degree be retarded by early, intensive control of
hyperglycaemia by insulin or oral therapies (reviewed recently in [7]). Macrovascular
pathologies are numerous and coronary artery disease (CAD) is common, regularly
manifesting itself earlier in life than in individuals without diabetes [8]. The anatomy of
atherosclerosis in patients with diabetes is distinct, regularly presenting as multivessel disease
characterised by diffuse and rapidly progressive lesions [9] that predispose to myocardial
ischaemia, infarction and stroke [10]. Peripheral arterial disease leads to critical limb
ischaemia and, together with impaired capacity to develop collateral vessels in T2DM,
increases the risk of lower limb amputations [11]. In addition, both coronary and peripheral
revascularisation procedures in patients with diabetes are problematic and the long-term
results are disappointing [12;13]. Increased arterial stiffness is a characteristic of T2DM
vessels [14] that undoubtedly impedes essential, adaptive remodelling in response to vascular
interventions. Vessel stiffening, together with increased thrombotic risk [15], augmented
intimal hyperplasia and restenosis [16;17] are key contributors to inferior prognosis and poor
outcomes after revascularisation in diabetes patients.
1.2 Glycaemic control and vascular complications
Individuals with insulin resistance and T2DM generally have coexistent conditions of
hyperglycaemia and hyperlipidaemia together with hypercoagulable tendency, all of which
impart vulnerability to complications [12]. Plasma levels of glycated haemoglobin (HbA1c)
provide a marker of average blood glucose levels over 8-12 weeks; in healthy individuals this
is typically 4.0 - 6.0%. In addition to being a diagnostic indicator of diabetes, HbA1c serves
as a marker of glycaemic control in individuals with established diabetes. Current guidelines
suggest that in T2DM patients HbA1c is ideally maintained therapeutically by insulin and/or
oral therapies ≤ 7.0% [7]. The DCCT and UKPDS studies concluded that this level of control 
was effective in retarding and preventing microvascular complications [7], yet the beneficial
effects on macrovascular complications were not evident, at least in the medium-term. Indeed,
early indications from the ADVANCE, VADT and ACCORD trials suggested that intensive
glycaemic treatment had little, if any additional benefit in patients with diabetes and clinical
CAD [7;18]. The ACCORD trial aimed specifically to achieve near-normal HbA1c levels
4(<6.0%) but unexpectedly this led to higher mortality in intensively treated patients (3.5 year
period) with established cardiovascular disease [19]. Nevertheless, it does appear that
beneficial macrovascular benefits may be achieved through intensive glucose lowering in
patients without established disease and followed up over a longer time frame. The continued
follow-up of UKPDS reported a sustained (10 years) reduction in cardiovascular events,
notably in patients in whom early glycaemic management was achieved [20]. Modest benefits
of intensive glycaemic control were also visible beyond 5 years of follow-up in both
ADVANCE and ACCORD [19;21]. Hence it appears that the advantage of glucose control
early in the course of T2DM may reduce cardiovascular events in the long term, and that the
conferred benefits are retained, even after a return to often inferior glycaemic control.
Importantly, the beneficial effect of previous glycaemic treatment was still evident 12 years
after the end of the DCCT trial; patients with type 1, insulin-dependent diabetes who received
prior intensive treatment exhibited significantly less macrovascular disease than those
allocated conventional treatment [22]. It is perhaps too simplistic to consider that glucose
alone is responsible for the vascular complications of T2DM and that successful management
of other risk factors of the metabolic syndrome such as obesity, hyperlipidaemia and
hypertension may lead to improvement of cardiovascular outcomes. Indeed, the outcome of
the Steno-2 trial [23] supported such a multifactorial approach.
2. Role of endothelial dysfunction in T2DM
The vascular manifestations associated with T2DM can be attributed to dysfunction of the
cellular components of the vasculature in a complex response to environmental stimuli [24];
the endothelium and smooth muscle cells (SMC) being key players. In health, the
endothelium plays a central role in vessel wall homeostasis by synthesising a critical balance
of vasodilators (of which nitric oxide (NO) is essential), and vasoconstrictors such as
angiotensin II, endothelin-1 and reactive oxygen species (ROS). NO generation in endothelial
cells (EC) is dependent on intact insulin signalling through the phosphoinositide 3-kinase
(PI3-K) /Akt pathway [25], and as such exerts beneficial vasorelaxant, anti-inflammatory and
antioxidant effects on the vasculature. NO production maintains blood pressure within
physiological ranges through promoting relaxation of medial SMC lying beneath the
endothelium. Endothelial dysfunction, a common early event in insulin resistance (“pre-
diabetes”) and T2DM, is characterised by a range of abnormalities, the most extensively
studied being decreased NO synthesis (reviewed in [26]). In these circumstances,
atherosclerosis is accelerated, blood pressure is elevated and a paradoxical coronary
vasoconstriction occurs. Indeed, reduced NO bioavailability is observed prior to the onset of
atherosclerotic structural changes and has been shown to predict the development of coronary
artery disease [27] and future cardiovascular events [28].
Endothelial function that precedes and contributes to the progression of cardiovascular
disease is a subject of global interest; its association with complications of T2DM is also well
studied (see [29-31] for recent reviews). By comparison, despite the pivotal role of the
vascular SMC in vessel wall remodelling and homeostasis, its function in the setting of
T2DM is less well explored. The purpose of this manuscript therefore is to review current
opinion specifically relating to vascular SMC phenotype and function in diabetes, and
evaluate new and novel targets that may be amenable to therapeutic manipulation.
3. The smooth muscle cell: critical effector of vascular function
3.1 SMC plasticity
Vascular SMC of blood vessel walls exhibit remarkable plasticity, switching between
differentiated and dedifferentiated phenotypes in response to changes in the local environment
(reviewed in [32]). In health, through signals from the endothelium, SMC maintain a
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only in vascular development but also in responding rapidly to adapt to environmental cues is
unequivocal. In the adult, this highly differentiated cell regulates vessel tone, diameter and
blood pressure through its key function – that of contractility. In these circumstances SMC
have a very low turnover and negligible synthetic activity. They express a specialised
repertoire of contractile proteins and cellular signalling molecules that is unique from other
cell types and is necessary to maintain vessel homeostasis (thoroughly reviewed in [32;33]).
Conversely, SMC dedifferentiation to a synthetic phenotype is an early event in numerous
cardiovascular pathologies including atherosclerosis [34], restenosis [35] and aortic aneurysm
disease [36]. These SMC are susceptible to proatherosclerotic stimuli that induce alterations
in organelle distribution, aberrant matrix metabolism and increased proliferation and
migration [32]. Such responses are in direct opposition to features observed in EC, that of
early senescence and apoptosis [37]. Within the vasculature the proportions of contractile and
secretory SMC are reported to vary, with the presence of distinct subpopulations that may
have implications for arterial disease [35]. Therefore, whilst phenotypic modulation is vital to
embryogenesis, vascular adaptation, remodelling and repair, it also augments progression of
vascular diseases such as atherosclerosis, hypertension, restenosis and bypass graft failure
[32]. The ability of SMC to maintain plasticity and respond appropriately is therefore critical
in this respect.
3.2 Influence of phenotype on SMC morphology and function
During the phenotypic modulation that is characteristic of a number of cardiovascular
disorders, SMC undergo morphological reorganisation. Differentiated SMC exhibit a highly
organised cytoskeleton with defined F-actin filaments that maintain contractile function,
expressing smooth muscle α-actin (SMA-α), smooth muscle myosin heavy chain (MHC), h1-
calponin, SM22α and smoothelin [38]. Stress fibre formation is promoted by binding of the 
accessory protein SM22α to actin filaments, inducing bundling and cell contractility. In 
contrast, dedifferentiated SMC exhibit loss of fibres and a diffuse, loose F-actin network,
concomitant with a reduction in SM22α [39]. The balance of SMA isoform expression in 
dedifferentiated cells therefore lies in favour of increased non-muscle β-actin and reduced 
SMA-α content and fibres [40]. Other key characteristics of dedifferentiated SMC are nuclear 
enlargement, increased ribosomal content and enlarged Golgi apparatus [41;42]. The ability of
SMC to spontaneously adopt a dedifferentiated phenotype in culture has greatly facilitated
laboratory research into such disorders [41].
Functionally, SMC dedifferentiation imparts proliferative and migratory capacity to
the cells through increasing sensitivity to stimulation by serum-derived mitogenic factors
[41]. Importantly, SMC alternate between contractile and synthetic states according to the
perceived environmental stimulus or external signal, indicating that phenotypic switching is
fully reversible. For example, in a rat carotid injury model, contractile SMC adopted a
synthetic phenotype after balloon injury, migrated to form a neointima and over time were
noted to revert to a contractile state [42].
3.3 Molecular regulation of SMC phenotype
Regulation of SMC phenotype is complex and has recently been thoroughly reviewed [34].
Switching of SMC between the differentiated and dedifferentiated state is regulated by a
variety of environmental stimuli, and as mentioned above, dedifferentiation is accompanied
by loss of SMC-specific marker genes such as SMA-α, and increased synthetic gene 
expression (reviewed in [32]). Most SMC marker genes are regulated by CArG box motifs
within their promoters which are bound by serum-response factor (SRF) that induces
transcription and differentiation. Principal co-activators of SRF are myocardin (MyoD) and
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kruppel-like factor (KLF) family of transcription factors are central regulators of SMC
phenotypic modulation and in particular KLF4, a key transcription factor in SMC switching,
can reduce the expression of MyoD leading to a reduction in SMC marker gene expression.
The KLF4 – MyoD – SRF axis is thus a central regulator of SMC
differentiation/dedifferentiation [43]. However, whilst much is known about the factors and
mechanisms that control SMC plasticity in cell culture conditions, in vivo evidence, for
example in native atherosclerosis in man or animal models, is still far from complete.
SMC phenotype in vitro is influenced by multiple factors but typically platelet-derived
growth factor BB (PDGF) promotes dedifferentiation [43] and transforming growth factor
beta (TGF-β) maintains cells in a differentiated state [44]. Recent evidence indicates that 
microRNAs (miRs) play a central role in the mechanisms determining SMC phenotype, not
only in cardiovascular development and function [45;46] but also linked to cellular
dysfunction in vascular diseases (reviewed recently in [47]). Whilst miR-1, miR-10a and
miR-145 are involved in directing the differentiation of stem cells into SMC [48-50], miR-21
was the first to be identified as a regulator of SMC differentiation and proliferation [51], but
later shown also to respond to TGF-β by promoting differentiation [52]. Furthermore, 
inhibition of miR-21 by PDGF promotes SMC migration [53]. Elevated miR-21 levels are
observed in rat neointimal lesions [51], human atherosclerotic peripheral arteries [54] and
hypoxic pulmonary artery SMC [55], driving proliferative and migratory responses.
Conversely, PDGF-induced expression of miR-221 [56;57] or miR-24 [58] promotes
dedifferentiation, reduced SMC marker gene expression and increased proliferation Perhaps
the most widely studied miRs at the level of the vascular SMC are miR-143/145, products of
the same bicistronic gene that are known to be highly expressed in the vascular wall,
particularly in SMC where they are reported to regulate SMC homeostasis and differentiation
to a contractile phenotype [59;60]. Downregulation of miR-145 is associated with neointima
formation in murine models of arterial injury [59;61]; conversely increased miR-145 levels
reduce proliferation by promoting SMC differentiation [48]. A recent report also
demonstrated miR-133 as a key regulator of SMC phenotype, inhibition of which exacerbated
proliferation and migration in vivo and in vitro [62]. In another study, transfection of miR-195
precursor reduced human SMC proliferation, migration and proinflammatory cytokine
secretion, conversely miR-195 was downregulated in balloon-injured rat arteries [63]. Given
the complexity of regulatory control of SMC phenotype (see Figure 1), it is therefore
unsurprising that multiple miRs appear to be involved and it is highly likely that others will be
discovered.
4. Can T2DM directly influence vascular SMC phenotype?
Although an immediate connection between T2DM per se and SMC phenotype is not clear,
the metabolic milieu of insulin resistance and T2DM can progress for a decade or more prior
to diagnosis [64]. During this gradual progression, “diabetic stimuli” particularly
hyperglycaemia and hyperinsulinaemia, can exert direct effects on all vessel wall cells,
potentially inflicting detrimental changes in phenotype and function and acceleration of
cardiovascular complications. Increased susceptibility to cardiovascular diseases in
individuals with T2DM suggests that a pathological “diabetes phenotype” may exist in
vascular SMC that is worthy of detailed study.
4.1 Disparities in SMC structure and function
Human studies are by their very nature usually restricted to ex vivo or in vitro investigation,
yet despite this restraint, studies in man have revealed important findings. In SMC cultured
from primary tissues in vitro, those of T2DM origin are morphologically distinct from ND
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valley, spindle-shaped appearance and adopt a more rhomboid phenotype [65;66]. Rhomboid
morphology appears to be characteristic of dedifferentiated, proliferative SMC that are
prevalent in vascular neointimal lesions [35], correlating with those reported in animal models
of type 1 diabetes [40;67]. However, the concept of a global switch from differentiated to a
dedifferentiated phenotype is unlikely. Co-existence of both synthetic (increased collagen
secretion) and contractile (expressing SMA-α) SMC populations in atherosclerotic lesions of 
diabetic mice support this notion [68]; suggesting that the critical factor directing vascular
function is the relative proportion of each SMC phenotype.
Saphenous vein (SV)-SMC from T2DM patients exhibit a marked disorganisation of
the F-actin cytoskeleton, a feature reproduced by Rho kinase (ROCK) inhibition in non-
diabetic (ND) cells [66]. Inhibition of ROCK suppresses neointimal formation in balloon-
injured rat arteries [69], an observation consistent with aberrant RhoA/ROCK signalling being
detrimental to the vasculature. Concordant with rhomboid SMC being more proliferative,
arterial SMC from T2DM patients also exhibit increased proliferative capacity compared to
their ND counterparts [65;70]. Interestingly, conditioned media from T2DM SMC was able to
promote proliferation of ND SMC, suggesting that the increased proliferation observed in
T2DM arterial SMC is dependent on a mitogenic factor secreted from the cells themselves
[70]. A more recent study demonstrated enhanced rate of cell cycle entry in arterial SMC
from patients with T2DM together with increased basal phosphorylation of p38 and ERK1/2
[71], signalling pathways that are associated with cell proliferation. Enhanced proliferation
has also been observed in SMC from both arterial (infragenicular) and venous (SV) sources
[65]. However, there is divided opinion in this respect; our studies observed consistently less
proliferation in T2DM SV-SMC compared with ND cells and no discernible difference in
ERK phosphorylation between the two populations [66]. The discrepant observations are
perceivably due to passage number and protocol employed to quantify proliferation (total
DNA fluorescence microscopy versus direct cell counting). It is also known that intrinsically
different proliferative capacities are apparent between SMC cultured from arterial and venous
sources, but also from different vascular beds [72].
Examination of intact human native vessels in vivo using ultrasound [73] and ex vivo
using functional and histological techniques [74] has indicated increased wall stiffness in
T2DM compared with ND individuals. Interestingly, the extent of structural abnormalities
observed in harvested SV grafts of T2DM patients was inversely correlated with the
efficiency of glycaemic control [74]. Consistent with increased tissue stiffness we reported
that SV-SMC from T2DM patients display increased numbers of large, vinculin-positive focal
adhesions. Notably, increased propensity to form focal adhesions is associated with both cell
stiffness and adhesion and is reportedly more prevalent in rhomboid SMC [66;75;76].
Accordingly, studies using arterial and venous SMC have reported increased adhesion in
T2DM-derived cells [65].
Early diagnosis of T2DM is difficult and up to half of newly diagnosed patients have
evidence of cardiovascular complications [4]. Owing to the essentially silent and progressive
nature of insulin resistance leading to T2DM, the vasculature is potentially exposed to a
variety of circulating metabolic disturbances for a prolonged period. Even transient exposure
to high glucose levels has been reported to inflict persistent phenotypic changes and altered
gene expression in cultured vascular cells [77]. Whilst hyperglycaemia per se is undoubtedly
a key trigger, hyperinsulinaemia, advanced glycation end products (AGEs) and raised levels
of proinflammatory cytokines and elevated plasma lipid levels, all of which are associated
with the diabetes phenotype [78], may also be important.
84.2 Insulin
Elevated plasma levels of insulin and glucose promote early senescence and apoptosis in EC
[37;79], and conversely vascular SMC are susceptible to growth-stimulatory effects of insulin
and insulin-like growth factors (IGF). Insulin induced primate aortic SMC proliferation in a
concentration-dependent manner [80] and, through a mechanism involving insulin-stimulated
release of IGF-1, induced proliferation of human arterial SMC [81;82]. Another study showed
a mitogenic effect of IGF-1 itself on human aortic SMC [83]. There is, however, speculation
that serially passaged SMC gradually lose the mitogenic response to insulin [84]. In our
laboratory, and in agreement with previous reports, we discovered that supplementation of
SV-SMC cultures with insulin increased proliferation concentration-dependently, whilst in
contrast, internal mammary artery (IMA)-SMC cultured from the same patients were entirely
resistant to insulin’s growth-promoting effects [85]. The autologous SV is routinely used to
revascularise diseased coronary vessels and, although the IMA is proven to be a more robust
conduit, its use is limited by availability. SV patency rates are generally poorer than IMA
grafts, and significantly inferior in the diabetic population, yet IMA patency rates are
comparable in both ND and T2DM patients [86;87]. Clearly the pathogenesis of graft intimal
hyperplasia is multifactorial; however the apparent lack of mitogenic effect of insulin on
IMA-SMC may offer an explanation for the superior patency rates of IMA grafts, even in
diabetic patients.
In a study of bovine aortic SMC, insulin-induced migration was mediated via mitogen
activated protein kinase (MAPK) signalling [88]. In our own studies, we demonstrated that
insulin also promoted chemotaxis of human SV-SMC [66;85]. In a separate study we
observed that cells of diabetic origin exhibited consistently higher migratory capacities than
those of non-diabetic origin when maintained in the presence of insulin [66]. It is tempting to
speculate that in the diabetic state the perceived “beneficial” effects of insulin signalling via
PI3-K are impaired, whilst the “detrimental” (proatherogenic, pro-restenosis) pathways may
predominate via preserved MAPK signalling. Treatment with exogenous insulin in T2DM
patients may potentially aggravate the already heightened susceptibility to cardiovascular
disease through its actions on SMC.
4.3 Glucose
In contrast to insulin, SMC responses to hyperglycaemia are reportedly variable. Glucose was
shown to increase proliferation of cultured human infragenicular SMC and together with
insulin it was synergistic [89]. Some other studies have reported a growth-promoting effect of
high glucose alone on vascular SMC from human aorta and umbilical artery (25 mM) [90],
and rat aorta (20 mM) [91;92]. A separate study reported that glucose-induced accelerated
SMC proliferation was attributable to downregulation of protein kinase C [93]. Other studies,
however, did not concur that glucose is mitogenic. For example, in porcine and human SMC
high levels of glucose did not modulate proliferation either alone or via synergism with other
SMC mitogens such as PDGF [94]. In agreement, our own studies using SMC cultured from
multiple patients under conditions of normal (5.5mM) and elevated (25mM) glucose, did not
identify any growth-modulating properties of glucose itself [66].
Irrespective of the direct influence of glucose on SMC function, it appears that
glycaemia and its capacity to inflict biochemical modifications to proteins may influence the
efficacy of pharmacological therapies, particularly anti-platelet therapies. Indeed, this was
exemplified by the Primary Prevention Project trial [95] in which cardiovascular risk
reduction with aspirin was ineffective in patients with diabetes. Several mechanisms have
been suggested that include glucose-induced inhibition of aspirin-mediated NO activity [96]
and modulating the activity of components of the coagulation cascade [97]. It is therefore not
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modify vascular SMC function, either beneficially or detrimentally.
4.4 Advanced glycation end products
Whilst glucose itself can directly impact SMC behaviour, it is important to consider other
consequences of chronic hyperglycaemia and importantly, that of formation of advanced
glycation end products (AGEs). These appear to contribute to development and progression of
cardiovascular disease in patients with T2DM through modification of the structure, function
and mechanical properties of tissues, cross-linking cellular proteins such as collagen and thus
inflicting tissue stiffening [98]. The composition of the extracellular matrix which also
impacts on tissue flexibility is predominantly regulated by SMC. Studies using intact IMA
from T2DM patients revealed a decrease in matrix-degrading metalloproteinases MMP-1 and
MMP-3, paralleled by increased matrix deposition [71]. Taken together, altered SMC
secretory function and aberrancies of ECM metabolism together could impact on vessel wall
rigidity. AGEs also activate specific receptors (e.g. RAGE) on numerous vascular cell types
including macrophages, EC and SMC, stimulating release of inflammatory cytokines, cell
adhesion molecules and profibrotic growth factors [99]. Vascular SMC derived from insulin-
resistant and diabetic db/db mice were shown to express elevated levels of RAGE, increased
inflammatory gene expression and increased cell migration that were attenuated by a RAGE
antibody [100]. AGE also increased proliferation and migration of human aortic SMC through
activation of the MAPK pathway and NFκB [101]. In arterial injury models, blockade of 
RAGE-ligand interaction reduced SMC proliferation and neointima formation in Zucker
diabetic rats [102] and similarly RAGE-deficient knockout mice exhibited less neointimal
hyperplasia, decreased SMC proliferation and reduced collagen deposition [103].
4.5 Lipids
Oxidised LDL (oxLDL) promotes a switch towards a synthetic SMC phenotype with
increases in proliferation, migration and apoptosis [63;104;105], cytoskeletal disruption [105]
and induction of inflammatory cytokines and MMPs [63;106] being reported. Elevated levels
of cholesterol and free fatty acids can also influence SMC phenotype. Interestingly,
cholesterol and oleic acid have been shown to induce atheromatous foam cell formation from
SMC, suggesting that not all foam cells are of macrophage origin [107;108]. Palmitic and
oleic acids also induce aberrant cellular function either directly or through paracrine
mechanisms by modulating SMC proliferation, migration and apoptosis [109-111]. The
combination of oxidative stress and dyslipidaemia common to T2DM patients likely impacts
on SMC through enhanced ability of lipid moieties in the oxidised state to activate key signal
transduction pathways [112].
4.6 Inflammatory cytokines
A key hallmark of T2DM is a state of chronic inflammation; proinflammatory cytokines,
amongst which interleukins (IL-1, IL-6), monocyte chemoattractant protein (MCP-1) and
tumour necrosis factor alpha (TNF-α) are prominent, are detected at elevated circulating 
levels in obese and diabetic individuals [113]. These stimuli induce SMC dedifferentiation,
increase proliferation and migration, and can induce further secretion of pro-inflammatory
mediators from the SMC themselves [114;115], exacerbating vascular dysfunction. Persistent
SMC inflammatory gene expression observed in murine models of T2DM appears to be
mediated through epigenetic modifications, through de-repression of the gene promoters
(reviewed in [116]). SMC established in vitro from these models exhibit a heightened
response to cytokine stimulation that appears to be retained in culture [117].
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Although the key metabolic disturbances of T2DM have been briefly described here,
this is by no means an exhaustive account and importantly, these stimuli do not exist or act in
isolation in the vasculature. It is clear that overlapping and complex interaction between
cellular and non-cellular components can influence SMC phenotype and function through a
diversity of intracellular signalling cascades and molecular mechanisms.
In adults the vascular SMC is a highly specialised cell whose key role is that of
contraction. The remarkable plasticity of the SMC is evidenced by its ability to undergo
phenotypic modulation during remodelling responses to vascular injury and in a variety of
disease states. This intriguing cell should perhaps not be categorised either as “contractile” or
“synthetic” as it can exist as a range of phenotypes with distinguishing features and regulatory
pathways (reviewed in [38]). Following on from our earlier description of a “T2DM SMC
phenotype” we have started to explore this further and have observed evidence of molecular
mechanisms that appear to discriminate between SMC of T2DM and ND origin
(unpublished). There is clearly a need to explore whether such mechanisms have an enduring
nature, and are apparent in vivo before considering their possible value as targets for
“correcting” the T2DM phenotype. A most challenging aspect is the existence of variable
degrees of heterogeneity between SMC populations from different patients and furthermore,
that the severity of the “T2DM phenotype” we have previously described [66] is almost
certainly influenced by other variables, including for example, degree of insulin resistance,
duration of T2DM and effectiveness of glycaemic control.
5. Evaluating SMC phenotype and function in animal models
The ideal animal model of metabolic syndrome and T2DM would present with obesity,
hypertension, dyslipidaemia and insulin resistance. T1DM and T2DM are unmistakable and
formally defined human diseases whereas it is clear that hyperglycaemia and its attendant
consequences are of multiple aetiological origins in animal models [118]. Therefore, whilst no
single animal model encompasses all the characteristics of human T2DM, many have proven
valuable in understanding pathophysiological mechanisms relevant to man (reviewed in
[118]). The utility of the high-fat fed C57/BL6 mouse has been acknowledged for close to two
decades [119], and from a practical point of view, rodent models are popular in the study of
both the pathogenesis and vascular complications of T2DM.
5.1. Murine models
Use of the db/db mouse model has increased understanding of vascular SMC
function/dysfunction. In this model which harbours mutations of the leptin receptor [120],
increased Ca2+ influx in cerebral arterial SMC led to vascular dysfunction, a phenomenon that
was mimicked by hyperglycaemic culture of rat cerebral artery SMC [121]. Another recent
study also reported disturbed Ca2+ homeostasis in SMC of db/db mice [122]. Disrupted SMC
contractile responses through disturbed clock gene expression [123] and increased COX-2
have been reported to induce SMC contractile hypereactivity [124]. Increased SMC
accumulation and matrix formation was reported to underlie augmented neointima formation
after vein bypass grafting in this murine model [125]. Importantly, SMC cultured from
diabetic db/db mouse aorta exhibited an increased inflammatory gene expression profile
compared to non-diabetic db/+ SMC and this was retained throughout several cell culture
passages [117;126], suggestive of a persistent “memory” of previous metabolic disturbance.
5.2 Rat models
The obese Zucker rat exhibits symptoms of metabolic syndrome; those of hyperlipidaemia,
obesity and insulin resistance, although with only mild hyperglycaemia. The Zucker diabetic
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fatty rat, (ZDF), which like the db/db mouse carries leptin mutations, rapidly becomes obese
and is hyperinsulinaemic, insulin resistant and hyperglycaemic [118]. Consistent with
observed vascular dysfunction in human T2DM, ZDF rats exhibit impaired resistance artery
remodelling [127] and also develop larger neointimas after arterial injury than lean (control)
Zucker animals [128]. The enhanced neointimal hyperplasia observed in the ZDF rat suggests
acquisition of a synthetic SMC phenotype – an assumption backed up by two separate studies
in the Goto-Kakizaki (GK) rat [129;130], a T2DM model exhibiting hyperglycaemia,
hyperinsulinaemia and accelerated atherosclerosis. In those studies, increased vascular SMC
proliferation and migration was attributable to increased ERK phosphorylation, an
observation confirmed in a separate study showing that both basal and IL-1β-stimulated levels 
of ERK activity were significantly higher in SMC from GK rats than in those from control
rats [131]. Perhaps of significant interest is the report that SMC cultured from the GK rat
exhibit both increased contractility and aberrant Rho kinase activation [132] which supports
the notion of a “mixed” SMC phenotype.
5.3 Porcine models
Rodent models are clearly most practical for laboratory study, yet large animal models of
T2DM, particularly porcine, are invaluable as they share greater compatibility with man in
terms of size and physiology. Enhanced atherosclerosis has been reported in two different
porcine models fed a high-fat diet, congruent with events in humans [133;134]. Ossabaw pigs
with diet-induced metabolic syndrome and coronary artery disease are reported to develop
augmented intimal hyperplasia after stent implantation, and isolated coronary SMC from
these animals exhibit marked dysfunction in Ca2+ influx [133]. Whilst enhanced intimal
hyperplasia would suggest a synthetic phenotype and aberrant Ca2+ handling indicative of a
contractile cell, these data together also support the idea of T2DM-SMC possessing some
characteristics of each phenotype.
6. Metabolic Memory: concept and evidence
6.1 Clinical trials
Reducing the significant healthcare burden of T2DM complications is a challenging task.
Although tight glycaemic control has been shown to ameliorate microvascular complications,
the reported benefits on cardiovascular events are controversial. As mentioned earlier,
progressive development of vascular complications as a result of prior exposure to
hyperinsulinaemia and hyperglycaemia appears to confer a persistent alteration of vascular
gene expression that has been termed “metabolic memory” [135]. Indeed, this proposal is
underpinned in the clinical setting in that ADVANCE, VADT and ACCORD; large clinical
trials that reported minimal impact of glycaemic control on cardiovascular benefit in patients
with diabetes and existing clinical CAD [7;18]. However, as discussed earlier, these trials
included individuals with a long history of diabetes with previously poor glycaemic control,
such that a “negative” metabolic memory theory would explain a reduced impact of
subsequent improved glycaemic control. This concept is corroborated by the UKPDS study,
in which only subjects with newly diagnosed diabetes were studied and early glycaemic
control led to a long-term improvement in both micro- and macrovascular complications [20].
The UKPDS investigators termed this phenomenon a “legacy” effect, thus supporting the
need for early control, not only of glycaemia but other associated metabolic abnormalities.
Follow-up studies of the DCCT trial revealed that early, intensive glycaemic control in type 1
diabetic patients led to sustained benefits and better macrovascular outcomes [135]. Indeed,
12 years on from the end of DCCT, a beneficial effect of prior glycaemic control was still
evident for atherosclerosis in much the same way as identified for microvascular disease [22].
It has recently been proposed that minimising early exposure to hyperglycaemia in
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T2DM is paramount [136], underpinning the idea that a change in cellular phenotype is not
easily and rapidly reversible by restoring glycaemic control at later time points. Therefore, in
the absence of early diagnosis of hyperglycaemia then alternative strategies to beneficially
modulate cell phenotype would be necessary and of considerable value.
6.2 Experimental studies
Experimental studies have revealed that transient high glucose exposure can induce persistent
phenotypic changes and altered gene expression in the vasculature. For example, in diabetic
mice progressive atherosclerosis was noted after restoration of normoglycaemia following a
period of hyperglycaemia [137]. Brief hyperglycaemia induced proinflammatory gene
expression in aortic EC of non-diabetic mice in vivo and in vitro, which was maintained even
after restoration of normal glycaemia [77]. Furthermore, SMC cultured from diabetic db/db
mouse aorta exhibited an increased inflammatory gene expression profile compared to non-
diabetic db/+ SMC that was retained throughout several passages [117;126]. In accordance,
we have observed a distinct phenotype in human SV-SMC of T2DM origin (reduced
proliferative capacity, rhomboid morphology, F-actin fragmentation) that is retained
throughout culture and passaging [66]. Taken together, these studies lend support to the idea
that loss of SMC plasticity in T2DM may compromise vascular function through an inability
to respond to environmental changes.
Thus, emerging perception is that prior metabolic disturbance and hyperglycaemia
leaves an early imprint on target cells of the vasculature and is potentially the origin of
epigenetic changes that favour vascular dysfunction that is difficult to reverse. Whilst
hyperglycaemia per se appears to be a key trigger, hyperinsulinaemia, AGEs and raised levels
of proinflammatory cytokines and lipids are hallmarks of a diabetes phenotype [78], and
likely to be of importance in this regard.
7. Current therapeutics
Although epidemiological studies advocate that tight metabolic control should impact
favourably on cardiovascular risk in diabetes (reviewed in [24]), it is clear that this goal is
not achieved effectively using current drug therapies (reviewed in [7;18]). It is interesting,
however, that some cardiovascular therapies are reported to influence SMC phenotype, at
least to some degree.
7.1 Statins
The cholesterol independent effects of statin therapy are clear [138]. It is reported that statin
therapy impairs SMC phenotypic modulation from contractile to synthetic state [139], and the
antiproliferative effect of statins on SMC improves SV bypass grafting [140]. On a cautionary
note, in the CORALL study, high doses of rosuvastatin modestly impaired glycaemic control
(HbA1c) in diabetic patients [141]; whilst another study concluded that in non-diabetic
individuals statin therapy reduced the incidence of cardiovascular events but conversely was
associated with an increase in the onset of T2DM [142].
7.2 Angiotensin Receptor Blockers (ARBs)
These widely used antihypertensive agents appear to improve vascular complications in
diabetes patients (reviewed in [143]), some effects being attributable to modulation of SMC
phenotype. Through blocking the effect of angiotensin II, ARBs reportedly regulate SMC
contractile function by preventing SMC dedifferentiation in atherosclerotic lesions, through a
mechanism involving NFAT5 [144]. SMC phenotype is also reportedly regulated by KCa3.1;
a calcium-activated potassium channel expressed by synthetic, rather than contractile, SMC
[145]. In that particular study of rodent arterial injury and also in a porcine model [146],
inhibition of KCa3.1 reduced neointima formation, thereby proposing a mechanism by which
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ARBs, through inhibition of KCa3.1, may prevent SMC dedifferentiation. Interestingly,
insulin treatment in rats has been recently shown to increase expression of KCa3.1 in SMC,
conferring a dedifferentiated phenotype and increased migration and proliferation [147].
Determining whether ARB therapy could reverse these effects would further inform their
capacity to control SMC phenotype.
In general, despite the routine use of drugs such as aspirin, statins, antiplatelet drugs,
ARBs, ACE inhibitors and other antihypertensive agents, increased cardiovascular disease in
patients with T2DM remains consistently higher than that of individuals without diabetes but
receiving similar therapies. The search for novel, alternative interventions is therefore a
rapidly expanding field.
Selective targeting of SMC phenotype holds promise for a variety of vascular
pathologies characterised by a remodelling response. These include hypertension, aneurysm
disease, atherosclerosis, restenosis, angiogenesis and wound healing [148]. Elucidating
distinct mechanisms that are responsible for particular features of SMC behaviour in vascular
diseases would provide exciting prospects for future therapies; recent advances in which will
now be briefly considered.
8. Moving towards novel therapies
Traditional risk factors for the development of T2DM are obesity, lack of exercise, smoking,
ethnicity; with an HbA1c above 6.0% being a useful marker. Although modulating the risk
factors can delay or prevent the development of T2DM [149], once established, reversing the
detrimental effect on the vasculature appears a challenging task. As mentioned above, and in
support of the reported “legacy” effect in the ACCORD, ADVANCE and VADT clinical
trials [7;18], we have observed that cultured SMC from T2DM individuals retain a distinct
phenotypic profile in vitro and throughout several weeks to months of subculturing [66]. Such
observations suggest that SMC are able to retain memory of previous metabolic disturbance
[150], whereby induced epigenetic changes persist even after the damaging stimulus is
removed, for example when normal plasma glucose levels are restored.
Current interests in molecular biomarkers encompass the fields of genomics,
transcriptomics, proteomics and metabolomics (reviewed in [151]). A variety of markers have
been suggested that may precede the development of cardiovascular disease, for example
plasminogen-activator-inhibtor-1 (PAI-1), interleukin-6 and phospholipase A2 [152] and are
all implicated in T2DM [153-155]. However, it is likely that these are effectors of SMC
dysfunction, rather than markers that originate directly from the SMC themselves that are
indicative of their phenotype.
8.1 MicroRNAs
(i) miRs as biomarkers of disease
Extensive research has shown that miRs are important in the regulation of diverse cellular
functions including those in the vasculature; hence aberrant expression may lead to
pathological states [156]. MiRs are also associated with multiple aspects of T2DM, with
changes in expression being reported in the liver, pancreatic beta cells, white adipose tissue
and skeletal muscle [157]. The potential for miRs as biomarkers has been exemplified in
studies whereby the plasma miR profile of T2DM and ND patients was examined. One
particular study reported reduced levels of a number of miRs including miR-21 and
endothelial miR-126 and importantly, the reduction of miR-126 in the plasma was observed
prior to the development of overt T2DM [158]. A different study focussed on several miRs
involved in the regulation of insulin gene expression, all of which were found to be increased
in the plasma of T2DM subjects [159]. However, these differences were not apparent in the
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pre-diabetes period, hence restricting their use as early biomarkers. Identifying miRs that are
directly linked to the T2DM SMC phenotype and subsequently investigating whether these
can be reliably detected in plasma samples is potentially of greater use.
(ii) miRs as therapeutic targets in T2DM
The evidence for miRs as regulators of SMC phenotype (introduced in section 3.3 above) is
well regarded and rapidly accumulating. Importantly, whilst several studies have implicated
roles for miRs in the pathogenesis of T2DM (reviewed in [157;160]), their role in diabetic
vascular complications is not widely studied. Reports are now emerging that associate altered
levels of a number of identified miRs with several diabetic cardiovascular complications
(reviewed in [116;160]); however, very little is known about how diabetes per se may
modulate phenotype and function of the SMC themselves and indeed, in vivo data is limited.
A recent study reported that enhanced levels of miR-125b were expressed in SMC of
diabetic db/db mice relative to control db/+ mice, suggesting that a miR-dependent
mechanism promotes a diabetic phenotype [161]. Levels of miR-143 and miR-145 are
increased in genetic- and diet-induced mouse models of obesity-associated insulin resistance
[162], yet a link with SMC phenotype has not been made to date. There is some evidence for
a role of miR-21 in diabetic complications, although both contributory [163] and protective
roles [164] in nephropathy are reported in mouse models. Increased miR-200 was very
recently shown to enhance inflammatory gene expression in vascular SMC from db/db mice
[165]. In that study the authors proposed that disruption of the negative regulatory loop
between miR-200 and a transcriptional repressor, Zeb 1 was a direct result of “diabetic
conditions”. Abundant expression of miR-195 has been demonstrated in human and rat
vascular SMC, that appears to be vasculoprotective in terms of reducing proliferation,
migration and inflammatory gene expression as a result of oxLDL exposure [63]. As
mentioned earlier, one of the hallmarks of T2DM is elevated levels of oxLDL, suggesting that
evaluation of miR-195 in SMC in the setting of T2DM is undoubtedly worthy of further
investigation. From evidence accrued to date, it seems likely that dysregulation of miRs
induced by the metabolic milieu may therefore feasibly contribute to altered gene expression
and aberrancies of SMC function in T2DM individuals, hence augmenting their
cardiovascular risk. Whilst some miRs may be perceived beneficial, yet others appear
harmful, detailed exploration of cell and species-specific expression and activity is therefore
imperative.
The clinical potential of miR therapies is substantial, and they have already been
explored in detail in a variety of cancers. Molecular tools for manipulating miR levels
(through inhibition or mimicry) have been an area of intense interest, rapid development and
ongoing refinement [166]. It is clear that miRs lend themselves to in vivo manipulation and
are currently in translational studies in oncology (reviewed recently in [167]). The future
potential of miRs with respect to cardiovascular complications in T2DM may lie in restoring a
functionally “normal” phenotype to SMC in the macrovasculature. However, it will be
essential to understand how particular miRs may direct the fate of the T2DM-SMC and
develop cell-targeted delivery strategies to explore them further. Importantly, consolidating
this knowledge using in vitro and in vivo studies, and subsequently translating to therapies in
man will be a challenging but potentially powerful approach.
8.2 Epigenetics
Whilst genetic factors are known to contribute to the pathogenesis of diabetes, the
study of epigenetic mechanisms - that of complex interactions between genes and the
environment is rapidly gaining momentum. Chromatin is a dynamic polymer into which
genomic DNA is packaged and its remodelling plays a key role in determining cellular
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phenotype. As mentioned earlier, this is a varied and complex process for which there is now
substantial evidence of epigenetic regulation, particularly with respect to acetylation and
methylation of histones in DNA (recently extensively reviewed in [38]). Chromatin
remodelling therefore appears to be central to determination of SMC fate through controlling
transcriptional access and recruitment of regulatory enzymes [168]. MiRs themselves can be
regulated epigenetically, for example through DNA methylation, although evidence accrued
to date is derived predominantly from cancer rather than cardiovascular studies (reviewed in
[169]). Epigenetic influences can have profound effects on gene expression that control cell
phenotype and function [170] and are believed to play roles in diabetes and its attendant
complications [171].
Changes in post-translational modifications on histones have been linked to gene
expression changes in diabetes [172]. Altered DNA methylation and histone
acetylation/methylation have all been observed in animal and cell models of diabetes and can
be induced by transient exposure to hyperglycaemia [77;117;137;172;173]. Hyperglycaemia
in EC has recently been shown to confer chromatin methylation signatures, resulting in
transcriptional modification of genes involved in EC dysfunction [174]. At the level of
vascular SMC, those derived from a murine model of diabetes retain proinflammatory and
proatherogenic features in culture [117], and in our own laboratory, the phenotypic anomalies
we observed in human T2DM-SMC of T2DM were stable over several passages in culture
[66], consistent with an underlying epigenetic mechanism that is inheritable through mitosis,
and requires further study.
It is simplistic to perceive diabetes as a state of hyperglycaemia. Rather, it is
complicated by multiple risk factors (discussed above), any or all of which can conceivably
induce epigenetic changes in chromatin structure, gene expression and ultimately modulate
SMC phenotype and function. Of relevance to the topic of this article, understanding how
epigenetic changes in SMC might underlie metabolic memory would be of extreme value.
The ongoing Human Epigenome project [175] should reveal greater levels of
understanding of how such changes regulate features of health and disease. Exploring the
relationship between epigenetics and miRs in diabetes complications is also an expanding
area of intense research activity [176], fuelled by recent discoveries that are beyond the scope
of this review. Their intricate interactions represent a means to not only understand molecular
mechanisms but to uncover novel therapeutic targets.
9. Summary and Conclusions
There is emerging support for a distinct and persistent vascular SMC phenotype that occurs
with T2DM (Fig. 2 & Table 1) although the evidence is tentative. Further detailed exploration
in this area to unambiguously define the characteristics of a T2DM-SMC phenotype will be
valuable in identifying new therapeutic targets. In vivo and in vitro studies indicate that
reinstating glucose control in the short to medium-term is itself insufficient to restore vascular
homeostasis and the scenario is clearly more complex. Cardiovascular complications of
T2DM are potentially driven by cellular dysfunction/aberrancies induced by metabolic
memory.
Substantial evidence suggests that early detection of T2DM is critical for prevention
of diabetes-related macrovascular disease, yet the natural history of the condition makes this
difficult. As a result, cardiovascular disease is already evident in around half of T2DM
patients by the time of diagnosis. Recent studies propose that plasma biomarkers are useful
for early detection of changes in SMC phenotype and function; a complete understanding of
the regulation of SMC dysfunction and identification of specific molecular markers would be
valuable. Therapies that target SMC to a reparative phenotype hold promise to effectively
“erase” metabolic memory and ameliorate cardiovascular disease in this population at risk.
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MicroRNA and epigenetic studies are an area of intense interest and these novel targets
already demonstrate significant promise for the future.
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